Skip to main content

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants

Open
  • Protocol code: MK-8591A-053
  • EudraCT code: No aplica
  • Research group: Infectious Diseases
  • Service: Infectious
  • Principal investigator:  Navarro Mercadé, Jordi
  • Pathology: Malalties del sistema respiratori
  • Phase: Fase II
  • Status: Recruiting volunteers